ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Dynamic imaging markers of incident microhemorrhages and superficial siderosis in the A4 study: A longitudinal person-interval analysis.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02008357 (Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionIncident microhemorrhages and superficial siderosis are hemorrhagic magnetic resonance imaging (MRI) abnormalities relevant to amyloid-related imaging abnormalities with hemosiderin deposition (ARIA-H) risk stratification, but evidence exploring their short-term dynamic predictors remains limited.
methodsWe analyzed longitudinal MRI data from the A4 study, constructing a discrete person-interval dataset for modeling the short-term risk of incident hemorrhagic MRI abnormalities. Models incorporated baseline covariates, alongside dynamic variables of recent microhemorrhage accumulation and current microhemorrhage burden. The outcome was defined as two or more new microhemorrhages or one or more new superficial siderosis between consecutive MRI scans.
resultsAmong 1069 participants (3647 intervals), 171 hemorrhagic events occurred. Both current burden (time-to-event: odds ratio [OR] 1.37, 95% confidence interval [CI] 1.09-1.73; all-event: OR 1.24, 95% CI: 1.04-1.49) and recent microhemorrhage accumulation were independently associated with an increased risk of hemorrhagic events (time-to-event: OR 1.83, 95% CI 1.01-3.30; all-event: OR 1.43, 95% CI: 1.00-2.04). DISCUSSION: Temporal imaging variables may provide independent prognostic information beyond baseline risk, supporting a dynamic model of hemorrhagic risk in Alzheimer's disease. CLINICAL
trial registrationClinical trial of Solanezumab for older individuals who may be at risk for memory loss (A4) (NCT02008357).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.